Dr. Reddy's Laboratories is India's leading pharmaceutical company with presence in over 100 countries. Dr Reddy's manufactures a range of products such as Active Pharmaceutical Ingredients, Generic & Branded Finished Dosages, Specialty Pharmaceuticals, and Biopharmaceuticals.
Dr. Reddy's Laboratories was founded in 1984 by Dr Anji Reddy. In 1986,
Dr. Reddy's went public and entered international markets with exports
of Methyldopa. In 1987, Dr. Reddy's obtained its first USFDA approval
for Ibuprofen API and started its formulations operations. In 1988, Dr.
Reddy's acquired Benzex Laboratories Pvt. Limited to expand its Bulk
Actives business. In 1990, Dr. Reddy's, entered a new territory when it,
for the first time in India, exported Norfloxacin and Ciprofloxacin to
Europe and Far East. In 1993, Dr. Reddy's Research Foundation was
established and the company started its drug discovery programme. In
1994, Dr. Reddy launched a GDR issue of US$ 48 million. In 1995, the
company set up a joint venture in Russia. In 1997, Dr. Reddy's became
the first Indian pharmaceutical company to out-license an original
molecule when it licensed anti-diabetic molecule, DRF 2593
(Balaglitazone), to Novo Nordisk. In 1998, Dr. Reddy's licensed
anti-diabetic molecule, DRF 2725 (Ragaglitazar), to Novo Nordisk. In
1999, the company acquired American Remedies Limited, a pharmaceutical
company based in India. In the year 2000, became the first Asia Pacific
pharmaceutical company, outside Japan, to be listed on the New York
Stock Exchange. In 2001, Dr. Reddy's Laboratories became India's third
largest pharmaceutical company with the merger of Cheminor Drugs
Limited, a group company. In 2002, Dr. Reddy's made its first overseas
acquisition - BMS Laboratories Limited and Meridian Healthcare in UK. In
2003, Dr. Reddy's launched Ibuprofen, first generic product to be
marketed under the "Dr. Reddy's" label in the US. In 2006, Dr.
Reddy's achieved a revenue of US$ 1 Billion. In the same year, Dr.
Reddy's acquired Betapharm- the fourth-largest generics company in
Germany. Today, Dr. Reddy's Laboratories is leading pharmaceutical
company in India in terms of turnover and profitability.
Products of Dr. Reddy's Laboratories
Active Pharmaceutical Ingredients (API): Dr. Reddy's
Laboratories product list span 24 major chemistries including
stereo-selective synthesis, cryogenics, hydrogenations and cyanations.
It has filed 84 US DMFs, the highest in India and second highest in the
Custom Pharmaceutical Services: Dr. Reddy's executes
cost-effective and time-bound projects for its customers, and provides
them cGMP-compliant products manufactured in FDA-inspected,
Generic Dosages: Dr. Reddy's Lab is a leading generic drugs
manufacturer. It is the fourth largest player in Germany after the
acquisition of betapharm. The company has expertise in customer-specific
packaging, compliance packaging, anti-counterfeit packaging, and has won
several awards globally for its packaging efforts, including the Asia
Star, AmeriStar and WorldStar awards.
Branded Dosages: Dr. Reddy's brands such as Omez (Omeprazole),
Nise (Nimesulide), Stamlo (Amlodipine), Ciprolet (Ciprofloxacin), Enam
(Enalapril) and Ketorol (Ketorolac) are leaders in their category in
Discovery Research: Dr. Reddy's is actively involved in
drug-discovery and clinical development programs.
Specialty Pharmaceuticals: In the field of speciality
pharmaceuticals, Dr. Reddy's deals in deals acquired proprietary
technologies, internally developed proprietary drug-delivery platforms,
and current internal compounds under pre-clinical and clinical
Biopharmaceuticals: Grafeel (Filgrastim) was the first biologics
product by Dr. Reddy's to enter the market. The company's second product
Reditux (Rituximab) is the first biosimilar monoclonal antibody to be
developed and launched anywhere in the world.
Major Achievements of Dr. Reddy's Laboratories: